Sucampo Pharmaceuticals — Investor Presentation (March 2015)
20 slides from Sucampo Pharmaceuticals's investor presentation, Mar 10, 2015
Slide 1: Sucampo Pharmaceuticals, Inc.
campo Pharmaceuticals, Inc. Stan Miele Senior Vice President, Sales & Marketing, President, Sucampo Pharma Americas, LLC e 9 SUCAMPO The Science of Innovation
Slide 2: Forward-Looking Statements
Forward-Looking Statements This pr tion “forward-looking " as that term is defined in the Private Securities igation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set fo
Slide 3: Investment Highlights
Investment Highlights = Lead product with differentiated profile in an attractive market with a large unmet need = Blue chip partnerships provide global reach and drive outsized revenue growth = Multiple levers available to drive sustainable long term growth = Robust product pipeline that will build
Slide 4: Clear Strategy to Methodically Build a Leading Bio/Pharma Company
Clear Strategy to Methodically Build a Leading Bio/Pharma.Company: Revenue & Market Value a os = Focus efforts and strengthen overall capabilities + Team + Development capability ™ Secure and grow AMITIZA revenues + Efforts to ensure consistent and sustainable growth + Global partnerships + Ongoing
Slide 5: Expanded Management Team with Considerable Experience in Product Development and Commercialization
@riistogenics lal AstraZeneca 2 Medimmune € centocor Grist Myers Squid [id] Atubex ens Zyngenta Alcon ESBATech Expanded CCG = Management SGlce mconst Team with - - Considerable : Max Donley 7 Execdive Vice b sarsent of testan Resources astrazenecs > lil Vivus Experience in Product Steven Caffé,M.D.
Slide 6: AMITIZA (lubiprostone)
amitiza lubiprostone e ? SUCAMPO Z The Science of Innovation
Slide 7: AMITIZA is a Unique and Highly-Differentiated Product
AMITIZA is a Unique and Highly-Differentiated Product = Most expansive label in constipation market: 3 indications, 3 patient types + CIC: Chronic Idiopathic Constipation + IBS-C: Irritable Bowel Syndrome with Constipation * OIC: Opioid Induced Constipation in Adults (non-cancer) = Most experienced
Slide 8: Large Market with Significant Unmet Need
-arge Market with Significant Unmet,Need | Brandi/Generic MATTY TRx 48.2 M TRx Sorbitol, Bulk Fiber (Citrucel, mineral oli [~ Benefiber) Linaclotide miner \, Sa Stoolsoftencrs 3% with stim lax (Genna 8) 4% Fleet Enemas (1%) Miralax, PEGS ‘Stimulant Laxatives (Ex-Lax, Duleoiax) Benty! (other IBS) ‘St
Slide 9: Evidence of Compelling Value Proposition
oO * U.S. h is Evidence of Compelling Value Proposition TRx Scripts 2014 total prescriptions were 1.3M all-time yearly high 4,950,000 4,300,000 | 4,250,000 1,200,000 1,180,000 1,100,000 1,050,000 4,000,000 2010 2011-2012, 2013-2014 Units “Based on Management assumption of 4 capsules porTRx 4,400,000
Slide 10: Drivers of Future AMITIZA Revenue
a ECU! ~ FUTURE REVENUE v Yearly Increases v wan ear ¥ Gross-to-net cap + Spliton net Gee 7 Undepentated ae markets with z unsatisfied patients Takeda v + Gross profit split reer on brand inl Y Physician Targeting v pIc v OIC driving 30% of brand sales Y Takeda - global partnership sus + Canada + EU
Slide 11: New Market Opportunities
New Market Opportunities Global pi of ranges from 5-18% U.K. CIC; OIC under review CIC and OIC NDA decision 2H:15 Switzerland us. CIC and OIC CIC, IBS-C and oIc Latin America TBD ROW Territories TBD Takeda is #1 GI company world wide Takeda has rights to all markets except Japan (Mylan) and China ne
Slide 12: AMITIZA Life Cycle Management
AMITIZA Life Cycle Managem Expand AMITIZA franchise through new formulation and new indication 1. New Formulation + Alternate formulation for additional adult and pediatric patients who cannot tolerate capsules, or naso-gastric tube fed patients * Incremental opportunity to address the roughly 40% o
Slide 13: Sucampo
SUCAMPO i The Science of Innovation $
Slide 14: At-A-Glance: Sucampo Pipeline
At-A-Glance: Sucampo Pipeline CLINICAL FOCUS ‘STAGE OF CLINICAL DEVELOPMENT TIMELINE TARGETS LEAD courounos rinses | ase 2 | puns Lubiprostone — Pediatric Functional Lubiprostone ~ Alterna a ‘open Laat Pediatric Functional Constipati 6 Feo z0I8 8 years) Har LP =. Cobiprostone— Ora © Cobiprostone - N
Slide 15: Supplementing Existing Pipeline
Supplementing Existing Pipeline © © © © © >) Commenced assessment of external programs Complement existing product pipeline Leverage current skills and experience of Sucampo Therapeutic areas Platform- and technology- agnostic Orphan and specialist products we SUCAMPO = The Science of Innovation
Slide 16: Sucampo
SUCAMPO iy The Science of Innovation $
Slide 17: Cash & Equivalents
Cash & Equivalents ‘$110.0M Notes Payable $25.8M Total Revenue $37.8M Net Income $9.3M EPS $0.21 AMITIZA U.S. Net Sales (as reported by Takeda for royalty calculation purposes): $91.1M Total Revenue $115.5M Net Income, excluding special items $17.9M EPS, excluding special items $0.40 AMITIZA U.S. Ne
Slide 18: Upcoming Milestones
Upcoming Milestones Expected Ting ‘Global partnership agreement for AMITIZA z] Updated on AMITIZA alternate formulation and PFC development T Filed AMITIZA (CIC and O16) for approval in Canada T Initiated MRP to secure approval for AMITIZA (CIC) in additional European markets v Decision made on jon
Slide 19: Investment Highlights
Investment Highlights = Lead product with differentiated profile in an attractive market with a large unmet need = Blue chip partnerships provide global reach and drive outsized revenue growth = Multiple levers available to drive sustainable long term growth = Robust product pipeline that will build
Slide 20: $ sucaMPo »
e $ sucaMPo » The Science of Innovation
Sucampo Pharmaceuticals — Investor Presentation (March 2015) on 6ix